Midomafetamine for combat disorders

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 11 Feb 2020: Trial registered, NCT04264026
  2. 29 Jul 2021: Trial started, NCT04264026

The trials

NCT04264026: MDMA-Assisted Psychotherapy in Veterans With Combat-Related, Refractory PTSD

State
Completed
Phase
Phase 2
People
5 taking part
Started
29 Jul 2021
Primary completion
1 May 2025
Arms
Open Label
Results
None posted
  1. 11 Feb 2020: Trial registered
  2. 29 Jul 2021: Trial started
  3. 1 May 2025: Trial completed

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Also known as 3,4 Methylenedioxymethamphetamine, 3,4-Methylenedioxymethamphetamine (MDMA), 3,4-methylenedioxymethamphetamine, 3,4-methylenedioxymethamphetamine (125 mg), Active Dose 1 (125 mg) MDMA HCl, Active Dose 2 (100 mg) MDMA HCl, Full Dose MDMA, Full Dose MDMA-assisted therapy (125 mg), Full dose MDMA-assisted therapy, Mdma, MDMA assisted psychotherapy, Open-Label Full Dose MDMA-assisted therapy (125 mg), methylenedioxymethamphetamine.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.